Share Fund
The objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of large cap and mid cap companies. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Suitability
This product is suitable for investors who are seeking
• Long term capital growth
• Investment predominantly in equity instruments of Top 100 companies by market capitalisationModerately High Leve
| Scheme Class | Equity |
| Scheme Category | Large & Mid- Cap |
| Expense Ratio | 1.16% |
| Min subscription | ₹ 5,000 |
| Scheme Type | Open-ended |
| Scheme AUM (in Crs.) | ₹ 3,749 |
| AMC AUM (in Crs.) | ₹ 1,59,694 |
| Min Addition Subscription | ₹ 1,000 |
| Benchmark Type | S&P BSE 200 India TR INR |
| Exit Load | Exit load of 1.0%, if redeemed between (0-1) years. No Exit load, if redeemed after 1 years. |
| Fund | Min SIP Inv. | Min Inv. | Returns 3Y |
|---|---|---|---|
IDFC Core Equity Fund - Direct Plan | 1000 | 1000 | 22.25% |
Principal Emerging Bluechip - Direct Plan | 1000 | 1000 | 0.38% |
Canara Robeco Emerging Equities - Direct Plan | 0 | 1000 | 15.13% |
| Company | Holding Type | Asset(%) |
|---|---|---|
HDFC Bank Ltd | Equity | 7 |
ICICI Bank Ltd | Equity | 5 |
Net Current Assets | Cash | 4 |
ITC Ltd | Equity | 4 |
Infosys Ltd | Equity | 3 |
Oracle Financial Services Software Ltd | Equity | 2 |
Reliance Industries Ltd | Equity | 2 |
Indus Towers Ltd Ordinary Shares | Equity | 2 |
Max Financial Services Ltd | Equity | 2 |
Aurobindo Pharma Ltd | Equity | 2 |
| Asset | Percent |
|---|---|
Equity | 96 |
Cash | 4 |
| 0 | |
Cash - Repurchase Agreement | 0 |
| Sector | Percent |
|---|---|
Financial Services | 31 |
Healthcare | 10 |
Consumer Cyclical | 10 |
Technology | 10 |
Basic Materials | 8 |
Fund Manager
V Srivatsa
7+ years of experience
About
pms_care@uti.co.in
Phone
1800 26 61230
Address
PMS Division, UTI - Tower, Gn Block, Bandra Kurla Complex, Mumbai- 400051, Mumbai - 400051
